Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

84 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-11-01

Study Completion Date

2017-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacogenetic Testing in an Outpatient Population of Patients With Depression

NCT02497027

Depression

COMPLETED NA

Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis

NCT02443584

Major Depressive Disorder

COMPLETED NA

Pharmacogenetics in Primary Care Psychotropics

NCT03232502

Depression Obsessive-Compulsive Disorder Generalized Anxiety Disorder

UNKNOWN PHASE3

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

NCT03537547

Major Depressive Disorder Depression Depressive Disorder +2 more

TERMINATED PHASE4

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

NCT02411123

Depression Anxiety

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants. Retrospective and prospective data will be collected on all subjects before and after pharmacogenetic recommendations have been made. Retrospective data will be collected for the previous 12 months before pharmacogenetic recommendations are made and prospective data will be collected for 12 months after pharmacogenomic recommendations have been made.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Care Coordination Group

Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'

Pharmacogenetic testing

Intervention Type GENETIC

Psychotropic genotyping panel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharmacogenetic testing

Psychotropic genotyping panel

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be taking either an anti-depressant or an anti-psychotic medication
* Must provide informed consent
* Must have Avera Health Plans insurance coverage
* Must have three months of participation in the Avera Care Coordination Program

Exclusion Criteria

* Must not be pregnant or breastfeeding
* Must not have an active and/or unstable diagnosis of substance abuse
* Must not have a primary diagnosis of dementia, bulimia, or anorexia nervosa disorder
* Must not have had a previous pharmacogenetic evaluation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No